Pay in 4 interest-free payments of $7.33 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
Thymosin beta 4 is unusual in this compound class for having controlled human data, RGN-259 ophthalmic solution has been assessed in randomised, placebo-controlled, double-masked Phase 2 and Phase 3 trials in severe dry eye and neurotrophic keratopathy (Sosne et al., Cornea 2015 and Int J Mol Sci 2023)
Peptide therapy has low toxicity, high potency, and high specificity for treating a wide range of health issues
10.1016/j.pharmthera.2017.02.014 38 HaoY.LiH.GeX.LiuY.YinJ.LiX.et al (2023)
Maintaining effective oral hygiene is crucial
BPC-157 (Tablets) CERTIFICATES OF ANALYSIS 1 COA BN-25BPT-500 Current Variant: Size: 500mcg BPC-157 519.25 mcg / 495.11 mcg / 482.91 mcg Small-Batch Research Confidence Focused research supply, documented batch by batch
Symptoms can include: Muscle weakness or cramping Irregular heartbeat Unusual tiredness
US$ 29.61
US$ 28.90
US$ 20.25
